Skip to main content

Table 2 Evaluation of the effect of HFCWO on subpopulation (normosecretive vs hypersecretive) along time

From: Chest physiotherapy improves lung aeration in hypersecretive critically ill patients: a pilot randomized physiological study

 

Normosecretive (n = 30)

Hypersecretive (n = 30)

 
 

T0

T1

T2

T3

T0

T1

T2

T3

pvalue

Not ventilated area (%)

0.2 [0.0; 2.9]

0.0 [0.0; 2.5]

0.0 [0.0; 1.8]

0.0 [0.0; 1.9]

0.6 [0.0; 2.7]

1.2 [0.0; 4.3]

0.4 [0.0; 3.7]

1.3 [0.0; 4.9]

0.082

TIV (mL)

444 [345; 539]

454 [372; 524]

447 [374; 536]

453 [358; 547]

474 [364; 540]

442 [363; 551]

461 [363; 555]

458 [363; 542]

0.123

 Dorsal

186 [142; 248]

188 [131; 259]

201 [132; 246]

210 [119; 252]

174 [143; 229]

161 [133; 224]

179 [145; 223]

169 [134; 221]

0.771

 Ventral

222 [169; 325]

248 [180; 319]

242 [185; 310]

234 [192; 307]

291 [212; 351]

285 [209; 360]

278 [197; 361]

281 [204; 336]

0.150

ΔTIV (mL)

0 [0; 0]

31 [− 28; 76]

− 7 [− 63; 65]

11 [− 20; 34]

0 [0; 0]

− 8 [− 38; 14]

− 3 [− 43; 34]

− 11 [− 44; 6]

0.117

 Dorsal

0 [0; 0]

9 [− 11; 31]

9 [− 37; 28]

7 [− 10; 27]

0 [0; 0]

− 3 [− 15; 12]

4 [− 12; 17]

2 [− 28; 17]

0.408

 Ventral

0 [0; 0]

7 [− 15; 37]

9 [− 28; 30]

7 [− 23; 28]

0 [0; 0]

− 4 [− 28; 9]

− 5 [− 36; 12]

− 9 [− 21; 8]

0.204

Centre of gravity (%)

51.9 [48.9; 54.6]

52.2 [49.8; 54.3]

51.4 [49.9; 54.0]

51.8 [48.6; 53.8]

54.8 [51.7; 57.1]

54.9 [51.6; 57.2]

54.6 [52.3; 56.9]

54.6 [51.5; 56.8]

0.054

ΔEELI (mL)

0 [0; 0]

− 22 [− 144; 73]

− 167 [− 47; 36]

− 98 [− 207; 30]

0 [0; 0]

42 [− 46; 316]

269 [92; 464]*,a

131 [34; 453]*,b

< 0.001

 Dorsal

0 [0; 0]

9 [− 39; 75]

− 6 [− 85; 94]

− 13 [− 146; 94]

0 [0; 0]

11 [− 44; 231]

97 [15; 431]*,a

67 [11; 373]*,b

< 0.001

 Ventral

0 [0; 0]

− 39 [− 134; 20]

−61 [−128; 12]

− 62 [− 188; 29]

0 [0; 0]

41 [− 60; 117]

115 [7; 238]*

59 [− 63; 194]*

< 0.001

Heart rate (beat/min)

84 (16)

85 (18)

84 (20)

82 (18)

80 (14)

80 (14)

77 (14)

75 (13)

0.916

Mean arterial pressure (mmHg)

86 (14)

86 (15)

85 (14)

85 (14)

88 (12)

88 (13)

85 (11)

83 (11)

0.811

Respiratory rate (breath/min)

18 (4)

18 (4)

18 (4)

19 (4)

18 (6)

19 (6)

19 (6)

18 (6)

0.954

pH

7.44 (0.06)

7.42 (0.06)

7.43 (0.06)

7.43 (0.06)

7.41 (0.06)

7.41 (0.06)

7.42 (0.05)

7.42 (0.05)

0.967

PaCO2 (mmHg)

40.9 (8.1)

42.2 (8.1)

41.7 (8.1)

41.8 (7.8)

44.3 (8.6)

44.3 (9.4)

43.7 (8.3)

43.4 (8.3)

0.952

PaO2/FiO2 (mmHg)

238 (75)

234 (65)

241 (61)

239 (60)

214 (56)

219 (59)

222 (55)

220 (52)

0.973

  1. T0 baseline assessment, T1 assessment soon after the end of the treatment, T2 assessment 1 h after the end of the treatment, T3 assessment 3 h after the end of the treatment, TIV tidal impedance variation, ΔTIV difference of TIV from T0, ΔEELI difference of end-expiratory lung impedance from T0, PaCO2 arterial partial pressure of carbon dioxide, PaO2/FiO2 ratio between arterial partial pressure and inspired fraction of oxygen
  2. *p < 0.05 normosecretive vs. hypersecretive within the same time point
  3. ap < 0.05 T0 vs. T2 within the same subpopulation
  4. bp < 0.05 T0 vs. T3 within the same subpopulation. All data are expressed as mean (standard deviation)